Journal of Genetic Disorders & Genetic Reports ISSN: 2327-5790

Reach Us +1 850 754 6199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, J Genet Disor Genet Rep Vol: 4 Issue: 2

RPOB Gene Polymorphism and its Association with Multi Drug Resistance Pattern of Mycobacterium Tuberculosis and Associated Risk Factors among TB Patients

Tekeba Sisay and Nega Berhane*
Department of Biotechnology, University of Gondar, North Gondar, Ethiopia
Corresponding author : Nega Berhane
Department of Biotechnology, University of Gondar, Gondar, Ethiopia
Tel: 251918149759
E-mail: [email protected]
Received: February 18, 2015 Accepted: March 25, 2015 Published: March 27, 2015
Citation: Sisay T, Berhane N (2015) RPOB Gene Polymorphism and its Association with Multi Drug Resistance Pattern of Mycobacterium Tuberculosis and Associated Risk Factors among Tb Patients. J Genet Disor Genet Rep 4:2. doi:10.4172/2327-5790.1000123

Abstract

RPOB Gene Polymorphism and its Association with Multi Drug Resistance Pattern of Mycobacterium Tuberculosis and Associated Risk Factors among TB Patients

Tuberculosis (TB) is the leading cause of death in the world due to bacterial infection. Despite the use of effective chemotherapy in the past years, drug-resistant TB especially multidrug resistance (MDR) is becoming a series challenge to compact . Rifampin (RIF) is one of the most important TB chemotherapeutic agents that act by inhibiting mycobacterial transcription, targeting DNA-dependent RNA polymerase (rpoB). The aim of the present study was to determine rpoB gene polymorphism and its association with Multi Drug Resistance (MDR) pattern of MTB by PCR and to determine the associated risk factors for drug resistance development. In this study rpoB mutations in the hot spot region (511-533 codons) were detected in 32 (69.6%) out of 46 smear positive (non-converged) MDR-TB patients and 5 (10.87%) out of 46 smear negative (converged) MDR-TB patients. However, there was not detected mutant allele in smear positive susceptible counter parts. The patients’ prior anti TB treatment history, HIV infection, origin of infection and drug misuse were found significant risk factors (p=.000, .000, .004, .000, respectively) for drug resistance development. The detection of mutations at 511-533 codons by PCR in 69.6% of non-converged MDR-TB patients indicated that most of drug resistance development is due to mutation at this position and the high prevalence of mutant rpoB allele.

Keywords: Tuberculosis; rpoB; MDR-TB; Rifampin

Track Your Manuscript

Share This Page

Media Partners

Associations